• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
5.64% $21.34

NEUREN PHARMACEUTICALS LIMITED - News & Media

Market Cap $2.725B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.More

Articles & Videos

Neuren flags Q4 DAYBUE sales of US$87m but shares take nosedive right out the gate

Neuren (ASX:NEU) shares were down -12% out the gate on Wednesday per CBOE live pricing, even as the stock flagged US$87.1M in sales of its flagship drug DAYBUE in Q4 of 2023.

28 Feb 2024 10:26 (AEDT)

"Things are worse": Neuren Pharmaceuticals shares sink as wonder drug questioned

ASX-listed Neuren Pharmaceuticals' (ASX:NEU) shares were down more than 13 per cent in lunchtime trades as the company is caught up in a short seller stoush.

16 Feb 2024 13:52 (AEDT)

Neuren Pharmaceuticals completes enrolment in Angelman syndrome phase two trial

Neuren Pharmaceuticals (ASX:NEU) has entered the last phase of screening for its phase two clinical trial using NNZ-2591 in AS, with all subjects now enrolled.

20 Dec 2023 10:51 (AEDT)

Neuren Pharma Reports positive results in phase 2 trial for NNZ-2591

Neuren Pharmaceuticals has unveiled findings from its Phase 2 clinical trial of NNZ-2591 in treating Phelan-McDermid syndrome

18 Dec 2023 10:31 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) expands global partnership with Acadia

Neuren (ASX:NEU) has announced its North American exclusive licence for the drug trofinetide has been expanded to a global licence.

14 Jul 2023 11:57 (AEST)

Neuren Pharamceuticals (ASX:NEU) opens first US site for Prader-Willi trial

Neuren Pharmaceuticals (ASX:NEU) has opened the first site in the United States for its phase two clinical trial in Prader-Willi syndrome.

28 Jun 2023 15:57 (AEST)

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

Neuren Pharmaceuticals' (ASX:NEU) North American partner, Acadia Pharmaceuticals, has had its treatment for Rett syndrome approved by the US Food and Drug Administration.

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

The US FDA has given Neuren Pharmaceuticals (ASX:NEU) the green light for a clinical trial testing its drug NNZ-2591 on children.

23 Jan 2023 11:16 (AEDT)



(20min delay)
Last
$21.34 		Change
1.140(5.64%) 		Mkt cap ! $2.725B
Open High Low Value Volume
$20.30 $21.65 $20.11 $14.34M 673.1K

Buyers (Bids)

No. Vol. Price($)
2 633 $21.30
 

Sellers (Offers)

Price($) Vol. No.
$21.34 2000 2
View Market Depth
Last trade - 16.10pm 15/05/2024 (20 minute delay) ?
Last
$21.37 		  Change
1.140 ( 5.63 %)
Open High Low Volume
$20.26 $21.64 $20.19 136487
Last updated 15.59pm 15/05/2024 ?
NEU (ASX) Chart

Top Stories

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial has been dosed.
Market Close: Materials win on critical minerals, hydrogen budget promises Renascor Resources (ASX:RNU) was the biggest winner gaining 30 per cent without market news, while Chalice Mining (ASX:CHN), Vulcan Energy Resources (ASX:VUL) and Aeris Resources (ASX:AIS) all gained between 7 and 10 per cent.
Want copper with that? Boss Energy hits orange metal on-site uranium play The exploration team at Boss Energy announced on Wednesday that its latest drill run on-site has successfully found copper.
Retail Revolution: Shekel Brainweigh leads the charge in Digital Inventory Management Industry specialist Shekel Brainweigh (ASX:SBW) has built AI into its high-tech product scale and weighing technologies.
Is IPO mania back for the ASX? Sun Silver jumps 100% on first day of listing Sun Silver is enjoying a strong debut on the local bourse with shares up 100% to 40cps as miners enjoy budgetary stimulus.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.